delirium patient admitted in ICU.
Conditions
Interventions
Intervention 1: Intervention group: olanzapine pill 5 mg, made by Marham Daroo Company and is prescribed orally every 8 hours to three days. Intervention 2: Control group: Halopiridolis pill 5 mg, ma
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria included patients over 18 years of age who had acute intoxication without dementia
Exclusion criteria
Exclusion criteria: Patients who take antipsychotic drugs for any reason Patients are using alcohol or benzodiazepine Patients who were allergic to haloperidol or olanzapine, Patients who have severe agitation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the symptoms of delirium: All symptoms related to decreased attention and memory impairment are eliminated. Response to treatment is based on changes in MDAS scores.impairment are resolved. The response to treatment is based on improvement in the MDAS score. Timepoint: Treatment results are evaluated by the researcher on days 3 and 5. Method of measurement: Delirio intensity is measured on the MDAS score, which includes 10 items and 4 points.This intensity will be rated in MDAS <= 15 as "mild", in 16 <= MDAS <= 22 as "moderate" and in 23 <= MDAS <= 30, it will be rated "severe". The remission index for this disease based on this score is MDAS values less than 10. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactJavad Mesbahi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed